ADVAIR DISKUS® 100/50 mcg inhalation powder pre-dispensed/GSK
Sponsors
Respirent Pharmaceuticals Co Ltd.
Conditions
Asthma
Phase 3
A Clinical Trial for Examining the Therapeutic Equivalence Between Fluticasone Propionate 100 mcg and Salmeterol 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 100/50 mcg Inhalation Powder/GSK in Patients With Asthma
CompletedNCT03676413
Start: 2018-10-02End: 2020-06-30Updated: 2020-07-07
Bioequivalence With Clinical Endpoint Study of Fluticasone Propionate 100 mcg and Salmeterol 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 100/50 mcg Inhalation Powder/GSK in Patients With Asthma
NCT05664061
Start: 2023-01-30End: 2023-12-31Target: 451Updated: 2023-03-01